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Background: Aristolochic acid (AA) is a nephrotoxicant associated with AA nephropathy (AAN) and upper urothelial tract cancer
(UUTC). Whole-genome sequences of 14 Romanian cases of renal cell carcinoma (RCC) recently exhibited mutational signatures
consistent with AA exposure, although RCC had not been previously linked with AAN and AA exposure was previously reported
only in localised rural areas.
Methods: We performed mass spectrometric measurements of the aristolactam (AL) DNA adduct 7-(deoxyadenosin-N6-yl)
aristolactam I (dA-AL-I) in nontumour renal tissues of the 14 Romanian RCC cases and 15 cases from 3 other countries.
Results: We detected dA-AL-I in the 14 Romanian cases at levels ranging from 0.7 to 27 adducts per 108 DNA bases, in line with
levels reported in Asian and Balkan populations exposed through herbal remedies or food contamination. The 15 cases from
other countries were negative.
Interpretation: Although the source of exposure is uncertain and likely different in AAN regions than elsewhere, our results
demonstrate that AA exposure in Romania exists outside localised AAN regions and provide further evidence implicating AA in RCC.
Aristolochic acid nephropathy (AAN) is characterised by chronic
renal disease with slow progression to terminal renal failure, and
transitional cell carcinoma of the upper urinary tract (UUTC)
(Debelle et al, 2008). Under the name of ‘Balkan Endemic
Nephropathy’ (BEN), it affects parts of Southeastern Europe
including some Romanian villages located in the Danube river
basin (Stefanovic and Polenakovic, 2009). Aristolochia clematitis is
endemic in the region and chronic exposure to aristolochic acid
(AA) probably originates from harvesting the herb together with
wheat, hence contaminating home-made and locally produced
flour ingested by the population (Stefanovic and Polenakovic,
2009). In Taiwan and other Asian countries, AA exposure is
attributed to usage of traditional Chinese herbs containing
Aristolochia (Debelle et al, 2008). The carcinogenic effect of AA
in the upper urinary tract includes a unique signature of otherwise
rare A:T4T:A transversions in the gene TP53 (Grollman et al,
2007; Chen et al, 2012) but also at the genome-wide level (Hoang
et al, 2013; Poon et al, 2013). The mechanism involved in the
carcinogenesis has been well described (Sidorenko et al, 2012;
Grollman, 2013). The AA reactive intermediates bind covalently to
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the DNA, creating bulky DNA lesions on the adenosine base: the
deoxyadenosine DNA adducts 7-(deoxyadenosin-N6-yl) aristolac-
tam I (dA-AL-I) and 7-(deoxyadenosin-N6-yl) aristolactam II
(dA-AL-II) that partially block DNA replication and give rise to
misincorporation of nucleotides (Attaluri et al, 2010).
Our recent whole-genome sequencing study of renal cell
carcinomas (RCCs) revealed that the AA-induced typical muta-
tional signature was very common in Romanian cases (12 out of 14
cases carried high rates of A:T4T:A transversions), and absent in
80 other cases diagnosed in the United Kingdom, Russian
Federation, and Czech Republic (Scelo et al, 2014). Although AA
is the only compound reported thus far to cause this mutation
pattern, the finding triggered further investigations because
(1) RCC was not known to be associated with exposure to AA;
(2) nontumour renal cortices of the 14 Romanian cases did not
show typical characteristics of chronic AA exposure, with no sign
of dense interstitial fibrosis or tubular atrophy; and (3) the
recruiting hospital was located in Bucharest although inhabitants
of the BEN area are usually hospitalised in Timisoara or Craiova
(two cities of the Western and Southwestern part of Romania;
Figure 1).
We sought to determine whether the observed mutational
A:T4T:A profile was due to AA exposure by measurement of AL-
DNA adducts in the nontumour renal cortex DNA samples of the
14 Romanian cases and 15 cases from other countries. As AL-DNA
adducts can persist for more than 20 years in the renal cortex
(Schmeiser et al, 2014), we also investigated the residential history
of the Romanian cases.
MATERIALS AND METHODS
Sample selection. Samples were selected for this study from
among 94 cases who went through whole-genome sequencing as
previously described (Scelo et al, 2014). All 14 Romanian cases
were selected for this study, and 15 additional cases were randomly
chosen among 80 cases from the United Kingdom, Russian
Federation, and Czech Republic (five cases in each country;
Supplementary Table 1). Samples were analysed with the
investigator blind to the country of origin of the samples. Written,
informed consent was obtained from each participant and the
study was approved by the relevant institutional review boards.
DNA isolation from nontumour renal tissue samples. Non-
tumour renal tissue samples were harvested immediately following
nephrectomy for renal cancer. Tissue samples were snap frozen
(Russia and United Kingdom) or preserved by immersion into
RNAlater (AMBION, Inc., Austin, TX, USA) and frozen (Romania,
Czech Republic). All samples were sectioned at IARC with
subsequent pathological review undertaken in Leeds (PH) to
confirm the absence of tumour cells, and to evaluate the presence
of tubules, glomerules, fibrosis, and inflammation (Scelo et al,
2014). Contiguous sections were also prepared for DNA isolation
that was undertaken at CEPH following a semiautomated
procedure on Autopure (Qiagen, Hilden, Germany) and with
samples from Romania also having further DNA extracts prepared
using a phenol/chloroform protocol at IARC. These additional
DNA extractions were undertaken in order to directly compare
DNA adduct levels with previous studies that used a phenol/
chloroform extraction protocol (Yun et al, 2015).
Enzymatic digestion of renal tissue DNA. DNA (5 mg) was
spiked with [15N5]-dA-AL-I and [
15N3]-dA-AL-II, synthesised as
previously described (Yun et al, 2012) at a level of 5 adducts per
108 DNA bases and incubated with DNase I and nuclease P1 for
3.5 h, followed by incubation with phosphodiesterase I and alkaline
phosphatase for 18 h at 37 1C. The DNA digest was dried by
vacuum centrifugation and reconstituted in 35 ml of 1 : 1 H2O/
DMSO. DNA quality and enzymatic digestion efficacy was assessed
by HPLC–UV on 10 randomly selected samples (5 from Romania,
2 from Czech Republic, 2 from the United Kingdom, and 1 from
Russia) (Yun et al, 2013). RNA contamination was o2% and
digestion efficiency of DNA went to completion for all samples.
Measurement of AL-DNA adducts by UPLC-ESI/MS3. Mass
spectrometry was employed to quantify dA-AL-I and dA-AL-II by
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Figure 1. Map of Romania showing counties affected by the Balkan endemic nephropathy (BEN; orange shaded) and counties of residence of
the 14 Romanian cases at the time of renal cell carcinoma diagnosis (yellow shaded). Number of cases in each county is indicated. Timisoara and
Craiova are the two cities where inhabitants from the BEN area are usually hospitalised (modified from http://commons.wikimedia.org/wiki/
File:Romania_counties_blank_big.png).
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the stable isotopic dilution method (Yun et al, 2012, 2014)
(Supplementary Figure 1). We used a NanoAcquity UPLC
system (Waters Corporation, Milford, MA, USA) interfaced
with an Advance CaptiveSpray source from Michrom Bioresource
(Auburn, CA, USA) and an ion-trap mass spectrometer
(LTQ Velos Pro; Thermo Fisher, San Jose, CA, USA). A Waters
Symmetry C18 trap column (180mm 20mm, 5 mm particle size)
was employed for online enrichment of the DNA adducts.
A Magic C18 AQ column (0.3 150mm, 3mm particle size;
Michrom Bioresources) was used for chromatography. The DNA
adducts were measured in the positive ionisation mode at the MS3
scan stage. The chromatographic and mass spectra acquisition
parameters have been described previously (Yun et al, 2012, 2013).
Statistical analysis. We performed a Wilcoxon rank-sum test
to compare the tumour A:T4T:A mutation loads using both the
number and the proportion of A:T4T:A mutations in subjects with
detectable vs subjects with undetectable adducts (available from
Scelo et al, 2014, and reproduced in Supplementary Table 1).
To analyse the correlation between the quantity of adducts and the
proportion of A:T4T:A mutations in tumours, we fitted a binomial
model with a logistic link function of log(dA-AL-Iþ 1) on
proportions of A:T4T:A weighted by the number of total mutations
(see Supplementary Notes). We calculated odds of A:T4
T:A mutations vs other mutation types (odds ratios (ORs)) for 1
log(dA-AL-I) increment and their 95% confidence intervals
(95% CIs).
Assessment of residential history in Romanian cases. County of
residence at the time of RCC diagnosis was available for all 14
Romanian cases. Five cases were successfully recontacted and
provided a full lifetime residential history. Since the 1980s, all
Romanian citizens are allocated with a personal identification code
that encodes the county of residence among other information.
Before its use became systematic in the 1990s, this could be either
the county of residence at the time of birth or the country of
residence at the time when the code was allocated to the individual.
Although there is no possibility to decipher between the two, we
nevertheless used this information (available for 13 cases) in search
for evidence that some cases may have lived in the BEN area at
some point in their life.
RESULTS
In all 14 Romanian cases, dA-AL-I was detected in DNA samples
obtained from the phenol/chloroform extraction method (range:
0.7–26.8 adducts per 108 DNA bases; Figure 2 and Supplementary
Table 1) and below the limit of quantification (0.3 adducts per 108
DNA bases) in all 15 non-Romanian cases. Only one Romanian
sample was below the detection threshold when using DNA
samples obtained from the Autopure extraction protocol. Thus,
our data show that dA-AL-I is stable towards tissue storage in
RNAlater and largely survives extensive DNA processing. Con-
sistent with previous studies, dA-AL-II was below the limit of
quantification in all subjects (Yun et al, 2015).
The load of A:T4T:A mutations in tumours was significantly
higher in the 14 Romanian samples with detectable dA-AL-I than
in the 15 other samples (Wilcoxon rank-sum test Po10 5
when comparing both the numbers and the proportions of
A:T4T:A mutations). Similar results were obtained when using
the adduct quantities measured on the DNA samples obtained
from the Autopure extraction method. The proportion of
A:T4T:A mutations was positively associated with the log
quantity of dA-AL-I adducts (odds of A:T4T:A mutations vs
other mutation types increased by 2.09 for 1 log(dA-AL-I)
increment (95% CI: 0.96–4.54, P¼ 0.0605; Figure 3). For two
Romanian cases, the histopathological review could not confirm
that the sample was from the renal cortex rather than medulla as
no glomeruli were present. However, removing these cases from
the regression did not substantially change the result (OR¼ 2.18,
95% CI: 0.98–4.84, P¼ 0.0560). Excluding from the analysis the
sample with the highest quantity of adducts also led to similar
result (OR¼ 2.20, 95% CI: 0.78–6.16), whereas the trend was
attenuated when restricting the analysis to the 14 cases with
detectable adducts (OR¼ 1.57, 95% CI: 0.45–5.37). Adding
potential confounders in the model – namely age, sex, body
mass index, history of hypertension and tobacco use, level of
fibrosis and inflammation in the renal cortex, and stage and grade
of the tumour – also did not change the association (ORs varied
from 1.98 to 2.30).
None of the 14 cases lived in the BEN area at the time of
diagnosis (Figure 1). Among five cases with available lifetime
residential history, none ever lived in the BEN area. All five had
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Figure 2. Levels of dA-AL-I adducts in 29 nontumour renal cortex samples from renal cell carcinoma cases of the Czech Republic (CZ), United
Kingdom (UK), Russian Federation (RU), and Romania (RO). The dot line indicates the limit of quantification (LOQ) value (0.3 adducts per 108 DNA
bases). Levels of adducts in Romanian samples were measured in duplicate: on DNA samples extracted with the standard Autopure (Qiagen)
protocol, and on DNA samples extracted using a phenol/chloroform protocol. Using the latest samples, cases from Romania harboured dA-AL-I at
levels ranging from 0.7 to 27 adducts per 108 DNA bases. The levels of adducts in all other cases were below the LOQ value.
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however moved from rural to urban areas. Two cases had lived in
counties closed to the BEN area, although both of them were on
the lower range of dA-AL-I (0.82 and 2.81 adducts per 108 DNA
bases). In addition, counties of the BEN area were not found in any
of the 14 personal identification codes.
DISCUSSION
In all 14 Romanian cases, dA-AL-I was detected at levels similar to
those reported in renal cortices of patients with UUTC in Taiwan
and the Balkans (Yun et al, 2015). The absence of dA-AL-II was
also consistent with previous studies.
The A:T4T:A mutations observed in Romanian tumour
samples have yet to be shown to drive the development of cancer,
and it remains premature to conclude a causal relationship exists
between AA exposure and RCC risk. In particular, although the
causal link with UUTC was partly established through the presence
of A:T4T:A mutations in the driver gene TP53 (Grollman, 2013),
it is unclear whether RCC driver genes are affected as TP53
mutations are rare in RCC and commonly mutated genes did not
show the A:T4T:A transversions (Scelo et al, 2014). Whole-exome
sequencing of eight RCC cases from endemic AAN regions in
Croatia also showed the AA signature in a subset of cases but failed
to identify specific driver genes (Jelakovic et al, 2015). Our results
leave no doubt that exposure to AA occurs in Romania outside of
the described endemic AAN regions. The findings reaffirm
previous observations that the dA-AL-I adduct in renal cortex
can serve as a biomarker of exposure to AA (Grollman, 2013;
Schmeiser et al, 2014). As dA-AL-I is a highly persistent lesion, we
could not however determine the timing or the source(s) of
exposure. As contamination of industrially produced flour with
Aristolochia sp. seeds is unlikely, the use of traditional therapeutic
remedies containing the plant should be urgently investigated as
potential contributors. The medical use of Aristolochia sp. is
allowed by the current Romanian legislation (Gluhovschi et al,
2010), and traditional remedies have been gaining popularity with
the increase of alternative/homeopathic medicine shops; studies
should be planned to investigate the consumption in the
population, and compare levels between kidney cancer cases,
chronic kidney disease cases, and healthy individuals. If AA is a
cause of RCC, public awareness of AA will have implications for
RCC prevention in other parts of the world where herbal remedies
containing AA is prevalent.
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